[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CU23318A7 - Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida - Google Patents

Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida

Info

Publication number
CU23318A7
CU23318A7 CU20030074A CU20030074A CU23318A7 CU 23318 A7 CU23318 A7 CU 23318A7 CU 20030074 A CU20030074 A CU 20030074A CU 20030074 A CU20030074 A CU 20030074A CU 23318 A7 CU23318 A7 CU 23318A7
Authority
CU
Cuba
Prior art keywords
particle size
compositions
tizoxanida
nitazoxanida
farmacã0
Prior art date
Application number
CU20030074A
Other languages
English (en)
Inventor
Jean-Francois Rossignol
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of CU23318A7 publication Critical patent/CU23318A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que contiene como agente activo por lo menos un compuesto seleccionado del grupo integrado por la fórmula I y la fórmula II. El agente activo tiene preferentemente la forma de partículas con un tamaÅ"o de partícula menor que 200 micrometros y un tamaÅ"o medio de partícula mayor que 10 micrometros. De manera preferente, las composiciones farmacéuticas están estabilizadas con por lo menos un ácido farmacéuticamente aceptable. Las composiciones farmacéuticas de la presente invención son útiles para el tratamiento de infecciones oportunistas en personas con el sistema inmune comprometido o suprimido, así como en el tratamiento de infecciones por tremátodos.</P>
CU20030074A 1997-05-07 2003-04-03 Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida CU23318A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (1)

Publication Number Publication Date
CU23318A7 true CU23318A7 (es) 2008-10-22

Family

ID=25313357

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030074A CU23318A7 (es) 1997-05-07 2003-04-03 Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida

Country Status (11)

Country Link
US (2) US5968961A (es)
AR (1) AR008355A1 (es)
BG (1) BG65679B1 (es)
CO (1) CO4950538A1 (es)
CU (1) CU23318A7 (es)
ID (1) ID24828A (es)
LT (1) LT4751B (es)
PL (1) PL193556B1 (es)
RO (1) RO122247B1 (es)
RS (2) RS49831B (es)
ZA (1) ZA983849B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20070015803A1 (en) * 2005-04-12 2007-01-18 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CN101448497B (zh) * 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
EP2395840B1 (en) 2009-02-13 2020-04-15 Romark Laboratories, L.C. Controlled release pharmaceutical formulations of nitazoxanide
AU2010247816B2 (en) 2009-05-12 2015-12-17 Romark Laboratories L.C. Haloalkyl heteroaryl benzamide compounds
AP2012006064A0 (en) 2009-06-26 2012-02-29 Romark Lab Lc Compounds and methods for treating influenza.
CA2836253C (en) 2011-05-16 2021-02-16 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
US20140306689A1 (en) 2013-04-10 2014-10-16 Texas Instruments, Incorporated High resolution current pulse analog measurement
EP3217795A4 (en) 2014-11-11 2018-08-22 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
CN108289961A (zh) 2016-03-31 2018-07-17 罗马克实验室有限公司 用于治疗病毒性感染的噻唑化物化合物
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
JP7502186B2 (ja) 2018-02-02 2024-06-18 リップル セラピューティクス コーポレーション ステロイド二量体を含むガラス製剤およびその使用
CN115956083A (zh) 2020-05-01 2023-04-11 波纹疗法公司 异二聚体组合物及用于治疗眼部病症的方法
EP4182304A1 (en) 2020-07-20 2023-05-24 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
WO2022046622A1 (en) 2020-08-24 2022-03-03 Romark Laboratories L.C. Use of thiazolides against coronaviruses
GB2625684A (en) 2021-10-05 2024-06-26 Council Of Scient And Industrial Research An Indian Registered Body Incorporated Under The Regn Of S An improved process for the preparation of nitazoxanide and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5496809A (en) * 1989-05-10 1996-03-05 Bristol-Myers Squibb Co Stable solutions of rebeccamycin analog
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
AP645A (en) 1994-04-13 1998-04-24 Romark Laboratories Lc Benzamine derivative, compositions containing said derivative and use thereof.
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
RS49831B (sr) 2008-08-07
ZA983849B (en) 1999-08-27
PL193556B1 (pl) 2007-02-28
LT4751B (lt) 2001-01-25
ID24828A (id) 2000-08-24
BG65679B1 (bg) 2009-06-30
AR008355A1 (es) 2000-01-19
RS50046B (sr) 2008-11-28
YU57199A (es) 2002-08-12
RS20070379A (en) 2008-06-05
CO4950538A1 (es) 2000-09-01
RO122247B1 (ro) 2009-03-30
LT99141A (en) 2000-08-25
US5968961A (en) 1999-10-19
US6117894A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
CU23318A7 (es) Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida
CO4810223A1 (es) Composiciones de champu estilizantes
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
ES2187467T3 (es) Composiciones liquidas de proteccion solar con buena deposicion y formacion de espuma.
ATE376423T1 (de) Gelierende wässrige pharmazeutische zusammensetzungen
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BR0311867A (pt) Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
BRPI0411872A (pt) composição farmacêutica
DE60108651D1 (de) Wärmegellierende bioabbaubare wässrige polymerlösung
AR078161A1 (es) Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EA200800950A1 (ru) Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
CO5140079A1 (es) Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
AR057242A2 (es) Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento
AR049063A1 (es) Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
ECSP034915A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
PE20230514A1 (es) Composiciones farmaceuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
DOP2000000091A (es) Composiciones farmaceuticas de la tizoxandia y la nitozoxandia
CU22990A3 (es) Composiciones farmacéuticas de la tizoxanida y la nitazoxadina
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih